On April 21, Jianfeng Group announced its annual report for 2024. The company's operating income was 2.88 billion yuan, down 0.6% year-on-year; the net profit attributable to parent company was 108 million yuan, up 15.2% year-on-year; the net profit deducted from non-parent company was 96.62 million yuan, up 48.8% year-on-year; Net operating cash flow was RMB412 million, representing a year-on-year increase of 871.3%; EPS (fully diluted) was RMB0.3138.
In the fourth quarter, the company's operating income was 854 million yuan, an increase of 3.1% over the same period last year. The net profit attributable to the parent company was successfully reversed from a loss of 34.68 million yuan in the same period last year, and the net profit attributable to the parent company was 37.43 million yuan. The net profit deducted from the non-parent company was successfully reversed from a loss of 48.21 million yuan in the same period last year, and the net profit deducted from the non-parent company was 38.12 million yuan; EPS is 0.1088 yuan.
By the end of the fourth quarter, the Company had total assets of RMB7.561 billion, representing an increase of 7.3% as compared with the end of the previous year, and net assets attributable to parent company of RMB5.187 billion, representing an increase of 1.5% as compared with the end of the previous year. In the annual report of 2024,
the company mentioned that due to the decline of the industry, the two major industries of building materials and medicine are facing greater pressure. The company has adopted the policy of "optimizing and adjusting to make up for shortcomings, reducing costs, improving quality and increasing efficiency", and has made great efforts to promote various production and operation work. Through technological transformation and energy saving and consumption reduction measures, the building materials business sector has improved production efficiency and environmental protection level. Specifically, subsidiaries such as Daye Jianfeng, Yunnan Jianfeng and Guizhou Jianfeng have made some achievements in technological transformation, especially in reducing production costs and environmental protection and emission reduction. In the
pharmaceutical business sector, the company actively promotes the optimization of the management system, draws lessons from the Amoeba management model, and improves the efficiency and cooperation of employees. In addition, during the reporting period, Jianfeng Pharmaceutical improved the quality of its main products through process optimization and quality control, and obtained the approval of a variety of drugs for marketing. These measures provide support for the company to maintain a certain market share in the highly competitive market environment.
On the same day, it announced that it planned to repurchase shares by means of centralized bidding transactions, with the repurchase amount not less than 20 million yuan and not more than 40 million yuan, and the repurchase price ceiling of 15 yuan per share. The repurchase period is within 12 months from the date of approval of the plan by the board of directors, and the repurchased shares will be used for employee stock ownership plans or equity incentives.
浙公网安备33010802003254号